Immunotherapy, based on targeting the programmed death-ligand 1(PD-L1)/PD-1, has been recently used to treat advanced non-small cell lung cancer (NSCLC) patients with no alteration in driver genes [1]. Here, CD274 is linked to non-small cell lung carcinoma.